Brazil has just approved its very first generic semaglutide pen, a groundbreaking moment following the expiration of the Ozempic patent. This exciting development opens the door to more affordable and accessible diabetes treatments, Reuters reports
Brazil has just approved its very first generic semaglutide pen, a groundbreaking moment following the expiration of the Ozempic patent. This exciting development opens the door to more affordable and accessible diabetes treatments, Reuters reports
